NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $9.24 -0.09 (-0.96%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.19▼$9.6250-Day Range$6.04▼$9.4852-Week Range$3.45▼$10.83Volume178,133 shsAverage Volume374,007 shsMarket Capitalization$403.88 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AxoGen alerts: Email Address AxoGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside32.6% Upside$12.25 Price TargetShort InterestBearish5.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.50) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 starsMedical Sector722nd out of 936 stocksElectromedical Equipment Industry18th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has only been the subject of 2 research reports in the past 90 days.Read more about AxoGen's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.58% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in AxoGen has recently increased by 13.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 1.9 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AxoGen this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for AXGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.50) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -18.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -18.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About AxoGen Stock (NASDAQ:AXGN)AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesJuly 23 at 7:00 AM | globenewswire.comAxogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024July 23 at 4:16 AM | americanbankingnews.comAxoGen (NASDAQ:AXGN) Shares Cross Above Two Hundred Day Moving Average of $7.95July 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.July 20, 2024 | sg.finance.yahoo.comAxoGen, Inc. (AXGN) stock historical prices & data – Yahoo FinanceJuly 1, 2024 | globenewswire.comCompany Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)June 24, 2024 | globenewswire.comAxogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™May 18, 2024 | ca.finance.yahoo.comALGN May 2024 350.000 callMay 16, 2024 | finance.yahoo.comAxogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®July 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 14, 2024 | finance.yahoo.comAxogen, Inc to Participate at Leerink Partners Healthcare Crossroads ConferenceMay 9, 2024 | markets.businessinsider.comBuy Rating Upheld for AxoGen Amid Strong Financials and Innovative Growth StrategyMay 6, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comAxoGen First Quarter 2024 Earnings: Misses ExpectationsMay 3, 2024 | finance.yahoo.comAxogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst ChallengesMay 2, 2024 | msn.comAxoGen Non-GAAP EPS of -$0.06 beats by $0.01, revenue of $41.4M misses by $0.65MMay 2, 2024 | globenewswire.comAxogen, Inc Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comHere's what Wall Street expects from AxoGen's earnings reportMay 1, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) is largely controlled by institutional shareholders who own 58% of the companySee More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+32.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,720,000.00 Net Margins-12.99% Pretax Margin-12.99% Return on Equity-22.18% Return on Assets-11.06% Debt Debt-to-Equity Ratio0.72 Current Ratio3.43 Quick Ratio2.23 Sales & Book Value Annual Sales$159.01 million Price / Sales2.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book4.15Miscellaneous Outstanding Shares43,710,000Free Float40,646,000Market Cap$403.01 million OptionableOptionable Beta1.11 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 62)Chairman, President & CEO Comp: $1.49MMr. Erick DeVinney (Age 48)Chief Innovation Officer Comp: $557.9kMr. Harold D. TamayoVice President of Finance & Investor RelationsMr. Marc A. Began (Age 56)Executive VP, General Counsel & Chief Compliance Officer Ms. Doris QuackenbushVice President of SalesMr. Jens Schroeder KempChief Marketing OfficerDr. Ivica Ducic M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsZynexNASDAQ:ZYXINatus MedicalNASDAQ:NTUSEstablishment LabsNASDAQ:ESTAArtivionNYSE:AORTSilk Road MedicalNASDAQ:SILKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 13,798 shares on 7/26/2024Ownership: 0.368%Assenagon Asset Management S.A.Bought 1,248,823 shares on 7/18/2024Ownership: 2.999%Silvercrest Asset Management Group LLCBought 34,399 shares on 5/16/2024Ownership: 1.809%Kennedy Capital Management LLCSold 4,414 shares on 5/16/2024Ownership: 0.674%California State Teachers Retirement SystemSold 2,563 shares on 5/16/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $6.83 at the beginning of the year. Since then, AXGN shares have increased by 35.3% and is now trading at $9.24. View the best growth stocks for 2024 here. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings data on Thursday, May, 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The medical equipment provider earned $41.38 million during the quarter, compared to analyst estimates of $42.05 million. AxoGen had a negative trailing twelve-month return on equity of 22.18% and a negative net margin of 12.99%. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. Who are AxoGen's major shareholders? AxoGen's top institutional shareholders include Assenagon Asset Management S.A. (3.00%), Bank of New York Mellon Corp (0.37%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX) and Corbus Pharmaceuticals (CRBP). This page (NASDAQ:AXGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXGN Stock Alerts